Overview

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Status:
Recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and also to determine the recommended dose (RD) of E7090 in combination with other anticancer agents for subsequent phase studies.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Exemestane
Fulvestrant